Salvatore Calanna

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John Wilding, Rachel L. Batterham, Salvatore Calanna et al. · New England Journal of Medicine · 2021 · 4.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

Robert F. Kushner, Salvatore Calanna, Melanie J. Davies et al. · Obesity · 2020 · 275 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

Philip N. Newsome, Sven Francque, Stephen A. Harrison et al. · Alimentary Pharmacology & Therapeutics · 2019 · 183 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Sean Wharton, Salvatore Calanna, Melanie J. Davies et al. · Diabetes Obesity and Metabolism · 2021 · 162 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience

Bernard Zinman, Steven P. Marso, Erik Christiansen et al. · Diabetes Care · 2018 · 107 citations

Medicine, Pharmacology, Pharmacotherapy +17